Anna Beutler

5.2k total citations · 3 hit papers
53 papers, 3.5k citations indexed

About

Anna Beutler is a scholar working on Rheumatology, Hematology and Surgery. According to data from OpenAlex, Anna Beutler has authored 53 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Rheumatology, 16 papers in Hematology and 10 papers in Surgery. Recurrent topics in Anna Beutler's work include Rheumatoid Arthritis Research and Therapies (26 papers), Spondyloarthritis Studies and Treatments (20 papers) and Autoimmune and Inflammatory Disorders Research (15 papers). Anna Beutler is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (26 papers), Spondyloarthritis Studies and Treatments (20 papers) and Autoimmune and Inflammatory Disorders Research (15 papers). Anna Beutler collaborates with scholars based in United States, Canada and United Kingdom. Anna Beutler's co-authors include Gerald G. Krueger, Dafna D. Gladman, Arthur Kavanaugh, M. Mack, Désirée van der Heijde, Philip J. Mease, Kurt de Vlam, Cynthia Guzzo, Christian Antoni and C. Birbara and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and CHEST Journal.

In The Last Decade

Anna Beutler

53 papers receiving 3.4k citations

Hit Papers

Infliximab improves signs and symptoms of psoriatic arthr... 2005 2026 2012 2019 2005 2009 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    2005 553 citations Christian Antoni, Gerald G. Krueger et al. Annals of the Rheumatic Diseases profile →
  2. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study
    2009 462 citations Arthur Kavanaugh, Iain B. McInnes et al. Arthritis & Rheumatism profile →
  3. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial
    2008 444 citations Robert D. Inman, Désirée van der Heijde et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Beutler United States 27 2.6k 1.8k 1.3k 378 313 53 3.5k
Meliha C Kapetanovic Sweden 28 1.7k 0.7× 1.0k 0.6× 563 0.4× 206 0.5× 436 1.4× 67 2.7k
A. Hot France 35 907 0.3× 831 0.5× 771 0.6× 528 1.4× 532 1.7× 146 3.2k
Syuji Takei Japan 26 1.2k 0.4× 750 0.4× 1.2k 0.9× 456 1.2× 224 0.7× 108 2.7k
Elisabeth Märker‐Hermann Germany 25 2.0k 0.8× 1.6k 0.9× 661 0.5× 205 0.5× 236 0.8× 95 2.9k
Sebastiaan J. Vastert Netherlands 31 645 0.2× 1.3k 0.7× 1.7k 1.3× 626 1.7× 221 0.7× 124 3.4k
J. Dixey United Kingdom 23 1.8k 0.7× 301 0.2× 541 0.4× 233 0.6× 339 1.1× 49 2.6k
Andreas Reiff United States 31 1.8k 0.7× 982 0.6× 2.4k 1.9× 873 2.3× 183 0.6× 68 4.0k
Karyl S. Barron United States 26 732 0.3× 978 0.6× 600 0.5× 485 1.3× 169 0.5× 56 2.6k
Estibaliz Lazaro France 30 895 0.3× 1.1k 0.6× 315 0.2× 153 0.4× 348 1.1× 156 2.8k
Frank B. Vasey United States 27 1.0k 0.4× 687 0.4× 321 0.2× 388 1.0× 296 0.9× 63 2.0k

Countries citing papers authored by Anna Beutler

Since Specialization
Citations

This map shows the geographic impact of Anna Beutler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Beutler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Beutler more than expected).

Fields of papers citing papers by Anna Beutler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Beutler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Beutler. The network helps show where Anna Beutler may publish in the future.

Co-authorship network of co-authors of Anna Beutler

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Beutler. A scholar is included among the top collaborators of Anna Beutler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Beutler. Anna Beutler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, David, Allan L. Klein, David Cella, et al.. (2021). Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept. BMC Cardiovascular Disorders. 21(1). 201–201. 16 indexed citations
2.
Vecchié, Alessandra, Juan Guido Chiabrando, Aldo Bonaventura, et al.. (2020). Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America. CHEST Journal. 158(6). 2556–2567. 37 indexed citations
3.
Klein, Allan L., David Lin, Paul Cremer, et al.. (2019). Abstract 12851: Efficacy and Safety of Rilonacept in Recurrent Pericarditis: A Multicenter Phase 2 Clinical Trial. Circulation. 5 indexed citations
4.
Klein, Allan L., David Lin, Paul Cremer, et al.. (2019). RILONACEPT IN RECURRENT PERICARDITIS: FIRST EFFICACY AND SAFETY DATA FROM AN ONGOING PHASE 2 PILOT CLINICAL TRIAL. Journal of the American College of Cardiology. 73(9). 1261–1261. 8 indexed citations
5.
6.
Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2013). The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Annals of the Rheumatic Diseases. 73(6). 1107–1113. 98 indexed citations
7.
Hsia, Elizabeth C., John J. Cush, Eric L. Matteson, et al.. (2012). Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care & Research. 65(2). 309–313. 48 indexed citations
8.
Kavanaugh, Arthur, D. van der Heijde, Iain B. McInnes, et al.. (2012). 5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 64(10). 1 indexed citations
9.
10.
Deodhar, Atul, et al.. (2011). Sustained Clinical Response with Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of a Randomized, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 1 indexed citations
11.
Emery, P., R. Fleischmann, Désirée van der Heijde, et al.. (2011). GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES. Lara D. Veeken. 50. 119–120. 1 indexed citations
12.
Kavanaugh, Arthur, D. van der Heijde, D. Gladman, et al.. (2010). GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY. Lara D. Veeken. 50. 143–143. 9 indexed citations
13.
Kavanaugh, Arthur, Iain B. McInnes, Philip J. Mease, et al.. (2009). Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study. Arthritis & Rheumatism. 60(4). 976–986. 462 indexed citations breakdown →
14.
Gómez‐Reino, Juan J., D Halter, Kurt de Vlam, et al.. (2007). Treatment with infliximab is associated with "Major clinical response" in psoriatic arthritis patients treated with infliximab: Analysis of two double-blind placebo controlled trials.. Document Server@UHasselt (UHasselt). 2 indexed citations
15.
Heijde, Désirée van der, Arthur Kavanaugh, Dafna D. Gladman, et al.. (2007). Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis & Rheumatism. 56(8). 2698–2707. 140 indexed citations
16.
Schlesinger, Naomi, Henrik Schumacher, Anna Beutler, et al.. (1998). SERUM URIC ACID IN ACUTE GOUT. AUTHORS' REPLY. PubMed Central. 57(7). 443–444. 5 indexed citations
17.
Beutler, Anna, H. Ralph Schumacher, Alan P. Hudson, Wael Salameh, & Judith A. Whittum‐Hudson. (1995). In Situ Hybridization for Detection of Inapparent Infection With Chlamydia trachomatis in Synovial Tissue of a Patient With Reiter’s Syndrome. The American Journal of the Medical Sciences. 310(5). 206–213. 30 indexed citations
18.
Nanagara, Ratanavadee, Feng Li, Anna Beutler, Alan P. Hudson, & H. Ralph Schumacher. (1995). Alteration of chlamydia trachomatis biologic behavior in synovial membranes suppression of surface antigen production in reactive arthritis and reiter's syndrome. Arthritis & Rheumatism. 38(10). 1410–1417. 102 indexed citations
19.
Beutler, Anna, Judith A. Whittum‐Hudson, Ratanavadee Nanagara, Harold R. Schumacher, & Alan P. Hudson. (1994). Intracellular location of inapparently infecting Chlamydia in synovial tissue from patients with Reiter's syndrome. Immunologic Research. 13(2-3). 163–171. 41 indexed citations
20.
Beutler, Anna, et al.. (1993). Calcium pyrophosphate dihydrate crystal deposition in synovium. relationship to collagen fibers and chondrometaplasia. Arthritis & Rheumatism. 36(5). 704–715. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meliha C Kapetanovic Breakdown of academic impact, for papers by A. Hot Breakdown of academic impact, for papers by Syuji Takei Breakdown of academic impact, for papers by Elisabeth Märker‐Hermann Breakdown of academic impact, for papers by Sebastiaan J. Vastert Breakdown of academic impact, for papers by J. Dixey Breakdown of academic impact, for papers by Andreas Reiff Breakdown of academic impact, for papers by Karyl S. Barron Breakdown of academic impact, for papers by Estibaliz Lazaro Breakdown of academic impact, for papers by Frank B. Vasey
Rankless by CCL
2026